{"schema_version":"1.0","type":"article","title":"摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳","url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.md","lang":"zh-Hant","date":"2026-07-01","publish_at":"2026-07-01T10:30:00+08:00","updated_at":"2026-07-01","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","ADHD","centanafadine","Otsuka","臨床數據","神經科學","美時","瑩碩生技"],"summary":"Otsuka 的 ADHD 新藥 centanafadine 公布成人 ADHD 合併焦慮症 IIIb 期積極結果，FDA 已接受 NDA 並給予優先審查。這不只是新藥進度，也反映 ADHD 治療正在從單一路徑走向更多機制與病人分層。","key_points":[],"facts":[],"sections":["01｜ADHD 不只是「過動」，更常被焦慮、憂鬱與情緒困擾放大","02｜Centanafadine 的關鍵，不只是有效，而是三條神經傳導路徑一起調節","03｜緩釋技術很重要：ADHD 不是只有白天上課才存在","04｜ADHD 治療不是「讓孩子變乖」，而是讓大腦有機會被好好使用","05｜台灣 ADHD 用藥可近性","結語｜真正該被摒棄的，不是孩子，而是把 ADHD 當成品行問題的舊觀念","參考資料"],"references":[{"title":"[Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults]","source":"","date":"","url":"https://www.otsuka-us.com/"},{"title":"[Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety]","source":"","date":"","url":"https://www.otsuka-us.com/"},{"title":"[Centanafadine Demonstrates Statistically Significant, Clinically Relevant Improvements in ADHD Symptoms]","source":"","date":"","url":"https://www.pharmacytimes.com/"}],"images":[{"alt":"ADHD 與焦慮共病，常讓注意力、情緒與執行功能問題互相放大","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-01.png"},{"alt":"Centanafadine 同時調節正腎上腺素、多巴胺與血清素相關神經傳導路徑","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-02.png"},{"alt":"每日一次延釋膠囊的治療目標，是讓症狀控制更穩定覆蓋日常生活","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-03.png"},{"alt":"台灣 ADHD 用藥可近性，牽涉進口、學名藥、供應穩定與區域授權布局","url":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-01）。摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳。https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-01-adhd-centanafadine-phase3b-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}